Lab21 Expands Companion Diagnostic Cancer Testing Service Internationally
News Jul 18, 2008
Lab21 now offer its newly launched K-RAS gene mutation and its epidermal growth factor receptor (EGFR) mutation testing services to its international customers.
The Company has seen the demand for K-RAS testing increase 10 fold since its launch at the beginning of the year and, with recent investment in people and systems, Lab21 is set to ramp capacity by 10 fold again to cope with the projected demand.
Recent drug licences for Vectibix™ and Erbitux™ require analysis of the KRAS gene in the tumor to assess if a patient will respond to the therapy. Through its international logistics function, Lab21 is now able to assist UK and international healthcare providers in screening patients for this genetic mutation.
Lab21’s fully accredited laboratories based in Cambridge, UK are already receiving patient samples from around the world including the Middle East, mainland Europe and the US. “Through our dedicated help-line, strong logistics and high quality testing function we are able to provide rapid turnaround from as little as 5-days and tailored reporting for many overseas customers”, added Dr Berwyn Clarke, CSDO of Lab21.
Dr Aladdin Maarraoui, Mafraq Hospital Abu Dhabi, commented “I am grateful to Lab21 for providing such quick and high quality results for my patients as testing for K-RAS mutation gives me great comfort that I will offer targeted therapy to the group of patients that are likely to respond to it. This is the future of oncology, to offer designer drugs for the group of patients who have the targeted mutated gene”.